4D Molecular Therapeutics, Inc. (FDMT) Reports In-Line Q3 EPS

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q3 EPS of ($1.01), in-line with the analyst estimate of ($1.01).

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Taylor Devices (TAYD) Misses Q4 EPS by 31c
• Sk Hynix Union Is Finalising Wording Of Tentative Wage Deal, And Will Brief Its Members On The Terms This Afternoon- Reuters